{"id":945353,"date":"2026-03-18T08:36:37","date_gmt":"2026-03-18T12:36:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/"},"modified":"2026-03-18T08:36:37","modified_gmt":"2026-03-18T12:36:37","slug":"niagen-bioscience-to-present-at-the-38th-annual-roth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/","title":{"rendered":"Niagen Bioscience to Present at the 38th Annual ROTH Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Niagen Bioscience to Present at the 38th Annual ROTH Conference<\/b><\/p>\n<p>LOS ANGELES&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54453175&amp;newsitemid=20260318201122&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=e27df11f2dbf142118b68bb72602a4a6\">Niagen Bioscience, Inc.<\/a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Froth.meetmax.com%2Fsched%2Fevent_127123%2Fconference_home.html%3Fbank_access%3D0%26event_id%3D127123&amp;esheet=54453175&amp;newsitemid=20260318201122&amp;lan=en-US&amp;anchor=38th+Annual+ROTH+Conference&amp;index=2&amp;md5=076af887edba4085a8d20f77fbaad74f\">38th Annual ROTH Conference<\/a>, taking place at The Ritz-Carlton Laguna Niguel in Dana Point, California, from March 22 to 24, 2026.<\/p>\n<p>\nNiagen Bioscience CEO, Rob Fried, will participate in the Technologies Advancing Healthy Aging Panel on Monday, March 23, at 2:00 PM PT (5:00 PM ET). The panel will be livestreamed and available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FkKmFFrbEes9oUCyrRFmQ5N%2FBreAtQUY7ixD84KRrBEiV7&amp;esheet=54453175&amp;newsitemid=20260318201122&amp;lan=en-US&amp;anchor=www.event.summitcast.com&amp;index=3&amp;md5=14cb528041c336af5f2828888e77a9e5\">www.event.summitcast.com<\/a>. Additionally, Niagen Bioscience\u2019s CEO, Rob Fried, and CFO, Ozan Pamir, will attend one-on-one meetings with institutional investors in person throughout the day.<\/p>\n<p>\nThis year\u2019s event will consist of one-on-one and small-group meetings, analyst-selected fireside chats, industry keynotes, and panels, with executive management from hundreds of private and public companies across a variety of growth sectors in attendance.<\/p>\n<p>\nInvestors interested in arranging one-on-one meetings should contact their ROTH representative. To learn more and submit a registration request, click <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.meetmax.com%2Fsched%2Fevent_127123%2Fconference_register.html%3Fbank_access%3D0%26event_id%3D127123&amp;esheet=54453175&amp;newsitemid=20260318201122&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=bffb907e61b549c042c289e46969359f\">here<\/a>.<\/p>\n<p>\nThe Technologies Advancing Healthy Aging Panel will be livestreamed and available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FkKmFFrbEes9oUCyrRFmQ5N%2FBreAtQUY7ixD84KRrBEiV7&amp;esheet=54453175&amp;newsitemid=20260318201122&amp;lan=en-US&amp;anchor=www.event.summitcast.com&amp;index=5&amp;md5=9eb5dfa0c5c6fcb65179c8b17c2b4537\">www.event.summitcast.com<\/a>.<\/p>\n<p>\nFor additional information on Niagen Bioscience, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.niagenbioscience.com&amp;esheet=54453175&amp;newsitemid=20260318201122&amp;lan=en-US&amp;anchor=www.niagenbioscience.com&amp;index=6&amp;md5=0a03d9418bd6c7facf119892952cd823\">www.niagenbioscience.com<\/a>.<\/p>\n<p><b>About Niagen Bioscience:<\/b><\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54453175&amp;newsitemid=20260318201122&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=7&amp;md5=91c89c1e864a872ca7404f74b6caddf1\">Niagen Bioscience, Inc.<\/a> (NASDAQ: NAGE) is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience<sup>\u2122<\/sup> is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.<\/p>\n<p>\nThe Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.<\/p>\n<p>\nDistinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There\u2019s a better way to age.<\/p>\n<p>\nAt the heart of its clinically proven product portfolio is Niagen\u00ae (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company\u2019s consumer supplement, Tru Niagen\u00ae, the number one NAD+ boosting oral supplement in the United States\u2020 (available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.truniagen.com&amp;esheet=54453175&amp;newsitemid=20260318201122&amp;lan=en-US&amp;anchor=www.truniagen.com&amp;index=8&amp;md5=211cfedaef4343e03026eba1ccdb44ce\">www.truniagen.com<\/a>), and Niagen Plus\u2122, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.niagenplus.com&amp;esheet=54453175&amp;newsitemid=20260318201122&amp;lan=en-US&amp;anchor=www.niagenplus.com&amp;index=9&amp;md5=5270f6da49cbedf7f2d892605111202c\">www.niagenplus.com<\/a>). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.<\/p>\n<p>\nNiagen Bioscience\u2019s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.niagenbioscience.com&amp;esheet=54453175&amp;newsitemid=20260318201122&amp;lan=en-US&amp;anchor=www.niagenbioscience.com&amp;index=10&amp;md5=ce144fb99f18e32bda16a4a3ff945442\">www.niagenbioscience.com<\/a>, where copies of press releases, news, and financial information are regularly published.<\/p>\n<p><sup>\u2020<\/sup><i>Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 \u2013 Dec. 2025)<\/i><\/p>\n<p><b>About ROTH:<\/b><\/p>\n<p>\nROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Their full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&amp;A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.roth.com&amp;esheet=54453175&amp;newsitemid=20260318201122&amp;lan=en-US&amp;anchor=www.roth.com&amp;index=11&amp;md5=3f33acb373b574aa64104e53bf308aa4\">www.roth.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260318201122r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260318201122\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260318201122\/en\/<\/a><\/span><\/p>\n<p><b>Niagen Bioscience Media Contact:<br \/>\n<\/b><br \/>Kendall Knysch, Senior Director of Media Relations &amp; Partnerships<br \/>\n<br \/>310.405.5227<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:kendall.knysch@niagenbio.com\">kendall.knysch@niagenbio.com<\/a><\/p>\n<p><b>Niagen Bioscience Investor Relations Contact:<br \/>\n<\/b><br \/>Valter Pinto, Managing Director<br \/>\n<br \/>KCSA Strategic Communications<br \/>\n<br \/>212.896.1254<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Niagen@kcsa.com\">Niagen@kcsa.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Science Pharmaceutical Research<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260318201122\/en\/2414362\/3\/Niagen_Bioscience_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Niagen Bioscience to Present at the 38th Annual ROTH Conference LOS ANGELES&#8211;(BUSINESS WIRE)&#8211;Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the 38th Annual ROTH Conference, taking place at The Ritz-Carlton Laguna Niguel in Dana Point, California, from March 22 to 24, 2026. Niagen Bioscience CEO, Rob Fried, will participate in the Technologies Advancing Healthy Aging Panel on Monday, March 23, at 2:00 PM PT (5:00 PM ET). The panel will be livestreamed and available at www.event.summitcast.com. Additionally, Niagen Bioscience\u2019s CEO, Rob Fried, and CFO, Ozan Pamir, will attend one-on-one meetings with institutional investors in person throughout the day. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Niagen Bioscience to Present at the 38th Annual ROTH Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-945353","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Niagen Bioscience to Present at the 38th Annual ROTH Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Niagen Bioscience to Present at the 38th Annual ROTH Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Niagen Bioscience to Present at the 38th Annual ROTH Conference LOS ANGELES&#8211;(BUSINESS WIRE)&#8211;Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the 38th Annual ROTH Conference, taking place at The Ritz-Carlton Laguna Niguel in Dana Point, California, from March 22 to 24, 2026. Niagen Bioscience CEO, Rob Fried, will participate in the Technologies Advancing Healthy Aging Panel on Monday, March 23, at 2:00 PM PT (5:00 PM ET). The panel will be livestreamed and available at www.event.summitcast.com. Additionally, Niagen Bioscience\u2019s CEO, Rob Fried, and CFO, Ozan Pamir, will attend one-on-one meetings with institutional investors in person throughout the day. &hellip; Continue reading &quot;Niagen Bioscience to Present at the 38th Annual ROTH Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T12:36:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260318201122r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Niagen Bioscience to Present at the 38th Annual ROTH Conference\",\"datePublished\":\"2026-03-18T12:36:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/\"},\"wordCount\":614,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260318201122r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/\",\"name\":\"Niagen Bioscience to Present at the 38th Annual ROTH Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260318201122r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-03-18T12:36:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260318201122r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260318201122r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Niagen Bioscience to Present at the 38th Annual ROTH Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Niagen Bioscience to Present at the 38th Annual ROTH Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Niagen Bioscience to Present at the 38th Annual ROTH Conference - Market Newsdesk","og_description":"Niagen Bioscience to Present at the 38th Annual ROTH Conference LOS ANGELES&#8211;(BUSINESS WIRE)&#8211;Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the 38th Annual ROTH Conference, taking place at The Ritz-Carlton Laguna Niguel in Dana Point, California, from March 22 to 24, 2026. Niagen Bioscience CEO, Rob Fried, will participate in the Technologies Advancing Healthy Aging Panel on Monday, March 23, at 2:00 PM PT (5:00 PM ET). The panel will be livestreamed and available at www.event.summitcast.com. Additionally, Niagen Bioscience\u2019s CEO, Rob Fried, and CFO, Ozan Pamir, will attend one-on-one meetings with institutional investors in person throughout the day. &hellip; Continue reading \"Niagen Bioscience to Present at the 38th Annual ROTH Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-18T12:36:37+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260318201122r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Niagen Bioscience to Present at the 38th Annual ROTH Conference","datePublished":"2026-03-18T12:36:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/"},"wordCount":614,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260318201122r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/","name":"Niagen Bioscience to Present at the 38th Annual ROTH Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260318201122r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-03-18T12:36:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260318201122r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260318201122r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/niagen-bioscience-to-present-at-the-38th-annual-roth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Niagen Bioscience to Present at the 38th Annual ROTH Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=945353"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945353\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=945353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=945353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=945353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}